Product Information
CYCLOBENZAPRINE 7.5 MG TABLET is a generic product labeled by Unichem Pharmaceuticals (USA) Inc., priced at $0.2629 per EA under NDC 29300041401. Its NADAC has been published 294 times since Nov 18, 2020.
FDA first approved this application on Jul 5, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
7.5 mg/1
Manufacturer
Unichem Pharmaceuticals (USA) Inc.NDC
29300041401
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CYCLOBENZAPRINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA213324FDA Approved
7/5/2020
TE Code
AB
On Market Since
7/6/2020
Pharmacological Classes
Price Statistics
The NADAC for CYCLOBENZAPRINE 7.5 MG TABLET has been published 294 times since Nov 18, 2020, and over the history we have for it it has declined 80.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2629 per EA |
|---|---|
| All-time high | $1.4342 (Jul 14, 2021) |
| All-time low | $0.2402 (Aug 19, 2026) |
| 52-week high | $0.3384 |
| 52-week low | $0.2402 |
| Median price | $0.3848 |
| Average price | $0.6059 |
| Largest weekly change | -68.4% (Oct 19, 2022) |
| Weeks tracked | 294 |
| Tracking since | Nov 18, 2020 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Cyclobenzaprine hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Unichem Pharmaceuticals (USA) Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Cyclobenzaprine hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Muscle Relaxant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CYCLOBENZAPRINE 7.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for CYCLOBENZAPRINE 7.5 MG TABLET, manufactured by Unichem Pharmaceuticals (USA) Inc., is $0.2629 per EA (NDC 29300041401), effective Sep 30, 2026.
How has the price of CYCLOBENZAPRINE 7.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for CYCLOBENZAPRINE 7.5 MG TABLET has declined 80.1%. It has been tracked across 294 weekly CMS publications since Nov 18, 2020.
What are the highest and lowest recorded NADAC prices for CYCLOBENZAPRINE 7.5 MG TABLET?
Since Nov 18, 2020, the NADAC for CYCLOBENZAPRINE 7.5 MG TABLET has ranged from a low of $0.2402 (Aug 19, 2026) to a high of $1.4342 (Jul 14, 2021), with a median of $0.3848 per EA.
Are there cheaper alternatives to CYCLOBENZAPRINE 7.5 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of CYCLOBENZAPRINE 7.5 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CYCLOBENZAPRINE 7.5 MG TABLET?
CYCLOBENZAPRINE 7.5 MG TABLET (NDC 29300041401) is labeled by Unichem Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.